Ching Hon Pui

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Treatment of acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology and Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    N Engl J Med 354:166-78. 2006
  2. pmc A 50-year journey to cure childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Departments of Oncology and Pharmaceutical Sciences, St Jude Children s Research Hospital
    Semin Hematol 50:185-96. 2013
  3. pmc Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 30:2005-12. 2012
  4. ncbi request reprint Results of therapy for acute lymphoblastic leukemia in black and white children
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 290:2001-7. 2003
  5. ncbi request reprint Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
    Ching Hon Pui
    St Jude Children s Research Hospital and the University of Tennessee, College of Medicine, Memphis, TN 38105, USA
    Lancet 359:1909-15. 2002
  6. ncbi request reprint Rasburicase: a potent uricolytic agent
    Ching Hon Pui
    St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
    Expert Opin Pharmacother 3:433-42. 2002
  7. ncbi request reprint Childhood acute lymphoblastic leukaemia--current status and future perspectives
    C H Pui
    Leukaemia Lymphoma Division, Fahad Nassar Al Rashid Chair of Leukaemia Research at St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 2:597-607. 2001
  8. pmc Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
    C H Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 24:371-82. 2010
  9. doi request reprint Recent research advances in childhood acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, Tennessee 38105 2794, USA
    J Formos Med Assoc 109:777-87. 2010
  10. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011

Detail Information

Publications171 found, 100 shown here

  1. ncbi request reprint Treatment of acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology and Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    N Engl J Med 354:166-78. 2006
  2. pmc A 50-year journey to cure childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Departments of Oncology and Pharmaceutical Sciences, St Jude Children s Research Hospital
    Semin Hematol 50:185-96. 2013
    ..It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset. ..
  3. pmc Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 30:2005-12. 2012
    ..Treatment outcome for black patients with cancer has been significantly worse than for their white counterparts. We determined whether recent improved treatment had narrowed the gap in outcome between black and white pediatric patients...
  4. ncbi request reprint Results of therapy for acute lymphoblastic leukemia in black and white children
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 290:2001-7. 2003
    ..Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials...
  5. ncbi request reprint Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
    Ching Hon Pui
    St Jude Children s Research Hospital and the University of Tennessee, College of Medicine, Memphis, TN 38105, USA
    Lancet 359:1909-15. 2002
    ....
  6. ncbi request reprint Rasburicase: a potent uricolytic agent
    Ching Hon Pui
    St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
    Expert Opin Pharmacother 3:433-42. 2002
    ..Rasburicase is a safe and effective agent in the prevention or treatment of hyperuricaemia in cancer patients...
  7. ncbi request reprint Childhood acute lymphoblastic leukaemia--current status and future perspectives
    C H Pui
    Leukaemia Lymphoma Division, Fahad Nassar Al Rashid Chair of Leukaemia Research at St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 2:597-607. 2001
    ..Ultimately, treatment based on biological features of leukaemic cells, host genetics, and the amount of residual disease should improve cure rates further...
  8. pmc Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
    C H Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 24:371-82. 2010
    ..The next main challenge is to further increase cure rates while improving quality of life for all patients...
  9. doi request reprint Recent research advances in childhood acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, Tennessee 38105 2794, USA
    J Formos Med Assoc 109:777-87. 2010
    ..The ultimate challenge is to gain a clear understanding of the factors that give rise to childhood leukemia in the first place, and enable preventive strategies to be devised and implemented...
  10. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011
    ..We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group...
  11. ncbi request reprint Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?
    Ching Hon Pui
    Departments of Oncology and Pharmaceutical Sciences, St Jude Children s Research Hospital, and Colleges of Medicine and Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38105, USA
    Leuk Lymphoma 47:2431-2. 2006
  12. ncbi request reprint Can the genotoxicity of chemotherapy be predicted?
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet 364:917-8. 2004
  13. ncbi request reprint Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7936-41. 2005
    ..Our goal was to use the information to further refine therapy and advance cure rates...
  14. ncbi request reprint Childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
    Rev Clin Exp Hematol 6:161-80; discussion 200-2. 2002
    ..In the interim, prospective clinical trials have provided valuable clues that are further increasing the cure rate of childhood acute lymphoblastic leukemia...
  15. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 104:2690-6. 2004
    ..01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether...
  16. ncbi request reprint Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop
    C H Pui
    St Jude Children s Research Hospital, Memphis, TN, USA
    Leukemia 18:1043-53. 2004
  17. ncbi request reprint Acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 350:1535-48. 2004
  18. pmc Central nervous system disease in hematologic malignancies: historical perspective and practical applications
    Ching Hon Pui
    St Jude s Children s Research Hospital, Memphis, TN 38105, USA
    Semin Oncol 36:S2-S16. 2009
    ..In this article, we review current and past practice of intrathecal therapy in ALL and NHL and the risk models that aim to identify predictors of CNS relapse in NHL...
  19. pmc Treating childhood acute lymphoblastic leukemia without cranial irradiation
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:2730-41. 2009
    ..Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse...
  20. ncbi request reprint Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 349:640-9. 2003
    ..We determined the long-term survival and the rates of health insurance coverage, marriage, and employment among patients who had attained at least 10 years of event-free survival...
  21. ncbi request reprint International collaboration on childhood leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Int J Hematol 78:383-9. 2003
    ..Twinning" partnerships between a well-established individual institution or study group and a pediatric cancer unit in a developing country has proved to be the most successful strategy to date...
  22. ncbi request reprint Clofarabine
    Ching Hon Pui
    Leukemia Lymphoma Division, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105 2794, USA
    Nat Rev Drug Discov 4:369-70. 2005
  23. pmc Biology, risk stratification, and therapy of pediatric acute leukemias: an update
    Ching Hon Pui
    St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA
    J Clin Oncol 29:551-65. 2011
    ....
  24. ncbi request reprint New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA
    Nat Rev Drug Discov 6:149-65. 2007
    ....
  25. ncbi request reprint Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia
    C H Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 16:3768-73. 1998
    ..To reassess the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia (ALL)...
  26. doi request reprint T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Cancer Cell 15:85-7. 2009
    ....
  27. ncbi request reprint Toward optimal use of intrathecal liposomal cytarabine
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
    Leuk Lymphoma 48:1672-3. 2007
  28. ncbi request reprint Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma
    C H Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 19:697-704. 2001
    ....
  29. ncbi request reprint Genetic studies in acute lymphoblastic leukemia
    C H Pui
    Departments of Hematology Oncology and Pathology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Acta Paediatr Taiwan 41:303-7. 2000
    ....
  30. ncbi request reprint Neonatal leukemia: a nemesis for pediatric oncologists?
    Ching Hon Pui
    St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 47:234-5. 2006
  31. pmc Challenging issues in pediatric oncology
    Ching Hon Pui
    St Jude Children s Research Hospital and the University of Tennessee Health Science Center, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Nat Rev Clin Oncol 8:540-9. 2011
    ..Finally, palliative care should be included as an essential part of cancer management to prevent and relieve the suffering and to improve the quality of life of patients and their families...
  32. doi request reprint Current management and challenges of malignant disease in the CNS in paediatric leukaemia
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38015 2794, USA
    Lancet Oncol 9:257-68. 2008
    ..Perhaps the most formidable challenge is to treat children with CNS relapse after a short initial remission or cranial irradiation...
  33. ncbi request reprint Clofarabine
    Ching Hon Pui
    Leukemia Lymphoma Division, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Nat Rev Drug Discov . 2005
    ..It is the first new drug for paediatric leukaemia to be approved in more than a decade, and the only one to receive approval for paediatric use before adult use...
  34. doi request reprint Acute lymphoblastic leukaemia
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Lancet 371:1030-43. 2008
    ....
  35. ncbi request reprint Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia
    Sanne Lugthart
    Hematological Malignancy Program, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Cell 7:375-86. 2005
    ..The expression of these genes discriminated treatment outcome in two independent patient populations, identifying a subset of patients with a markedly inferior outcome (37% +/- 13% 5 year DFS)...
  36. ncbi request reprint A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia
    John Carl Panetta
    St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Cancer Chemother Pharmacol 50:419-28. 2002
    ..These differences provide mechanistic and treatment insights for lineage and ploidy differences in MTXPG accumulation in human leukemia cells in vivo...
  37. ncbi request reprint Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia
    Gaston K Rivera
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 103:368-76. 2005
    ..The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy...
  38. ncbi request reprint Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Haematol 123:243-52. 2003
    ..022); overt recurrence of AML within the subsequent 6 months was significantly more likely in the former group. The assay described here holds promise for guiding the choice of post-remission treatment options in children with AML...
  39. ncbi request reprint Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia
    Yasuhiro Okamoto
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Pediatr Hematol Oncol 25:696-703. 2003
    ..Viridans streptococci (VS) are a primary cause of infection and pneumonia in patients with neutropenia. The authors determined the incidence, clinical features, and complications of VS sepsis in children receiving chemotherapy for AML...
  40. pmc Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
    Jun J Yang
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    JAMA 301:393-403. 2009
    ..Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response...
  41. pmc Genome-wide study of methotrexate clearance replicates SLCO1B1
    Laura B Ramsey
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 121:898-904. 2013
    ..This study is registered at http://www.clinicaltrials.gov as NCT00005585 and NCT00005596...
  42. pmc Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics
    Leo Kager
    Hematological Malignancies Program, and Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Clin Invest 115:110-7. 2005
    ..These findings reveal distinct mechanisms of subtype-specific differences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatment failure in childhood ALL...
  43. pmc Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105 2794, USA
    Lancet Oncol 11:543-52. 2010
    ....
  44. ncbi request reprint Lymphoid gene expression as a predictor of risk of secondary brain tumors
    Mathew J Edick
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, University of Tennessee, Memphis, Tennessee, USA
    Genes Chromosomes Cancer 42:107-16. 2005
    ..These data suggest that gene expression profiling from accessible tissues may identify targets involved in therapy-related malignancies in unrelated tissues...
  45. pmc Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations
    Heng Xu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    J Natl Cancer Inst 105:733-42. 2013
    ..Although accumulating evidence indicates inherited predisposition to ALL, the genetic basis of ALL susceptibility in diverse ancestry has not been comprehensively examined...
  46. pmc Treatment outcome in older patients with childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:6253-9. 2012
    ..To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is unknown...
  47. pmc Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Blood 108:3997-4002. 2006
    ..Further, the systemic clearance of methotrexate, teniposide, etoposide, and cytarabine did not differ with BMI (P > .3). We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL...
  48. ncbi request reprint Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital and the University of Tennessee, Memphis, TN 38105, USA
    Blood 100:52-8. 2002
    ..Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome...
  49. ncbi request reprint Favorable impact of the t(9;11) in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 20:2302-9. 2002
    ..To determine the impact of MLL rearrangements on the outcome of children with acute myeloid leukemia (AML)...
  50. pmc Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation
    Hiroto Inaba
    Department of Bone Marrow Transplantation and Cellular Therapy, MS 1130, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:3991-7. 2012
    ..To measure longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation (HSCT)...
  51. pmc Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects
    Lisa R Treviño
    St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 27:5972-8. 2009
    ..Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL)...
  52. pmc Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia
    Deborah French
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 113:4512-20. 2009
    ..We conclude that acquired genetic variation in leukemia cells has a stronger influence on MTXPG accumulation than inherited genetic variation...
  53. pmc Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2
    Christian Flotho
    Department of Pathology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Blood 108:1050-7. 2006
    ..Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis...
  54. pmc A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
    Elaine Coustan-Smith
    Department of Hematology Oncology, and International Outreach Progrm, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 108:97-102. 2006
    ..Thus, this new assay would enable most treatment centers to identify a high proportion of children with ALL who have an excellent early treatment response and a high likelihood of cure...
  55. ncbi request reprint De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo
    Thierry Dervieux
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital and University of Tennessee, Memphis, 38105, USA
    Blood 100:1240-7. 2002
    ....
  56. ncbi request reprint Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis
    Gianluigi Zaza
    St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 104:1435-41. 2004
    ..These findings have established that TEL-AML1 ALL has significantly lower de novo purine synthesis and differential expression of genes involved in purine metabolism...
  57. ncbi request reprint Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia
    Mathew J Edick
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, and College of Pharmacy, The University of Tennessee, Memphis 38105, USA
    J Clin Oncol 21:1340-6. 2003
    ..To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL)...
  58. pmc Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia
    Jun J Yang
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 120:4197-204. 2012
    ..All trials are registered at www.clinicaltrials.gov or www.cancer.gov (COG P9904: NCT00005585; COG P9905: NCT00005596; COG P9906: NCT00005603; St Jude Total XIIIB: NCI-T93-0101D; and St Jude Total XV: NCT00137111)...
  59. pmc Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, MS 260, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:3625-32. 2012
    ..Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value...
  60. ncbi request reprint Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma
    Evguenia J Karimova
    Department of Radiological Sciences, Division of Diagnostic Imaging and Biostatistics, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 25:1525-31. 2007
    ..We determined clinical and imaging risk factors predicting clinical joint outcomes of femoral head osteonecrosis in pediatric patients with leukemia or lymphoma...
  61. ncbi request reprint Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia
    Shinji Kishi
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, University of Tennessee, Memphis, TN 38105, USA
    Blood 103:67-72. 2004
    ..Prednisone strongly induces etoposide clearance, genetic polymorphisms may predict the constitutive and induced clearance of etoposide, and the relationship between genotype and phenotype differs by race...
  62. pmc Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation
    Kevin R Krull
    Department of Epidemiology and Cancer Control, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Blood 122:550-3. 2013
    ..This trial was registered at clinicaltrials.gov as no. NCT00760656. ..
  63. ncbi request reprint Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia
    John T Sandlund
    Department of Hematology Oncology, St Jude Children s Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN 38105, USA
    Blood 100:43-7. 2002
    ....
  64. ncbi request reprint Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 48:10-5. 2007
    ..The association between race and outcome of treatment for childhood acute myeloid leukemia (AML) has not been adequately studied...
  65. pmc Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia
    Jitesh D Kawedia
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 119:1658-64. 2012
    ..019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse...
  66. pmc High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
    Wing Leung
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 118:223-30. 2011
    ..10; P = .01) at the time of transplantation. We concluded that transplantation has improved over time and should be considered for all children with very high-risk leukemia, regardless of matched donor availability...
  67. pmc A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia
    Christian Flotho
    Departments of Pathology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 110:1271-7. 2007
    ..Incorporation of the expression levels of these genes into existing strategies of risk classification could improve clinical management...
  68. pmc ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia
    Heng Xu
    St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:751-7. 2012
    ..We sought to determine the contribution of ARID5B single nucleotide polymorphisms (SNPs) to racial disparities in ALL susceptibility and treatment outcome...
  69. pmc Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
    Laura B Ramsey
    Pharmaceutical Sciences Department, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Genome Res 22:1-8. 2012
    ..8% of SLCO1B1's effects (1.9% of total variation) and had larger effect sizes than common NS variants. Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes...
  70. ncbi request reprint Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia
    Mary V Relling
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:3930-6. 2004
    ..Putative risk factors for osteonecrosis have included being female, white race, and older age. Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL...
  71. pmc Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
    Elaine Coustan-Smith
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 10:147-56. 2009
    ..We studied leukaemic cells, collected at diagnosis, to identify cases with ETP features and determine their clinical outcome...
  72. ncbi request reprint Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 20:4217-24. 2002
    ....
  73. pmc Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 116:98-105. 2010
    ..The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed...
  74. pmc Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia
    Jitesh D Kawedia
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    Blood 117:2340-7; quiz 2556. 2011
    ..Overall, older age, lower albumin, higher lipid levels, and dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic variation...
  75. ncbi request reprint Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 109:157-63. 2007
    ..Outcome after recurrence of childhood acute myeloid leukemia (AML) is poor. We performed this study to identify prognostic factors for recurrence and for survival after recurrence of AML...
  76. pmc Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:3293-300. 2011
    ..To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia...
  77. ncbi request reprint Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
    Mary V Relling
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 101:3862-7. 2003
    ..Even when children receiving irradiation were excluded, the incidence was still higher in those receiving G-CSF (P =.019). In the setting of intensive antileukemic therapy, short-term use of G-CSF may increase the risk of t-ML...
  78. ncbi request reprint Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia
    Jessica R Roberson
    Department of Hematology Oncology, St Jude Children s Research Hospital, and the University of Tennessee College of Medicine, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:542-8. 2008
    ..The percentage of myeloperoxidase (MPO)-positive blast cells is associated with prognosis in adult acute myeloid leukemia (AML), but this association is unsubstantiated in pediatric AML...
  79. ncbi request reprint Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia
    Scott C Howard
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    JAMA 288:2001-7. 2002
    ..Traumatic or bloody lumbar puncture (LP) reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic leukemia (ALL). Little is known about the risk factors for traumatic and bloody LP...
  80. doi request reprint Effect of race on the outcome of pediatric patients with Hodgkin's lymphoma
    Monika L Metzger
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 26:1282-8. 2008
    ..We examine the effects of race on clinical outcomes among children with Hodgkin's lymphoma (HL) treated with contemporary therapy at a tertiary care children's hospital...
  81. pmc Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial
    Torben S Mikkelsen
    St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA
    J Clin Oncol 29:1771-8. 2011
    ....
  82. ncbi request reprint Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies
    Javier G Blanco
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis TN 38105, USA
    Pharmacogenetics 12:605-11. 2002
    ..403), 6.5% vs. 12.5% in blacks (P = 0.508), and 69.6% vs. 75.0% in Hispanics (P= 0.663). Our data do not support an association between common CYP3A4, NQO1 or CYP3A5 polymorphisms and the risk of t-ML in children treated for ALL...
  83. pmc Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
    Jun J Yang
    St Jude Children s Research Hospital, Memphis, TN, USA
    Blood 112:4178-83. 2008
    ....
  84. ncbi request reprint Global gene expression as a function of germline genetic variation
    Deborah French
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Hum Mol Genet 14:1621-9. 2005
    ....
  85. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007
    ..Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia...
  86. pmc Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 108:3302-4. 2006
    ..9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens...
  87. doi request reprint Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia
    Landry K Kamdem
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pharmacogenet Genomics 18:507-14. 2008
    ..One of the adverse effects of glucocorticoids is hypertension. Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension...
  88. pmc NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    J Clin Oncol 28:955-9. 2010
    ..We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML...
  89. ncbi request reprint Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children
    Robert P Sanders
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Haematol 130:781-7. 2005
    ..Febrile and allergic transfusion reactions were rare in paediatric patients transfused with leucoreduced, irradiated blood products, whether premedication was used or not...
  90. ncbi request reprint Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma
    R C Ribeiro
    Department of Hematology-Oncology, St Jude Children's Research Hospital, 332 N, Lauderdale, Memphis, TN 38105-2794, USA
    Leukemia 15:891-7. 2001
    ..Therefore, the clinical usefulness of MR imaging as a screening tool for AVNB in this set of patients remains uncertain...
  91. ncbi request reprint Parvovirus B19 infection in a child with acute lymphoblastic leukemia during induction therapy
    R Y McNall
    Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA
    J Pediatr Hematol Oncol 23:309-11. 2001
    ..Intravenous immunoglobulin was administered and the patient's aplastic anemia resolved completely within 3 weeks. This highlights the importance of alertness to the possibility of parvovirus infection in children with cancer...
  92. pmc Germline genomic variants associated with childhood acute lymphoblastic leukemia
    Lisa R Treviño
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Nat Genet 41:1001-5. 2009
    ..86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts. We conclude that germline variants affect susceptibility to, and characteristics of, specific ALL subtypes...
  93. pmc Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
    S Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1406-9. 2009
    ..These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse...
  94. ncbi request reprint Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience
    B I Razzouk
    Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
    Leukemia 15:1326-30. 2001
    ..They also suggest that dose intensification of etoposide and addition of 2-CDA may also offer an advantage. This study underscores the dependence of the prognostic impact of cytogenetic features on the efficacy of treatment...
  95. ncbi request reprint Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma
    Himesh Gupta
    Department of Surgery, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Surg 42:998-1001; discussion 1001. 2007
    ..We determined the incidence, presentation, stage, and outcome of children with Burkitt lymphoma presenting with intussusception...
  96. ncbi request reprint Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome
    W Leung
    The Department of Hematology-Oncology, St Jude Children's Research Hospital, 332 N. Lauderdale Street, Memphis, TN 38105, USA
    Bone Marrow Transplant 27:717-22. 2001
    ..Immune function 1 year after transplantation and the incidences and spectra of late sequelae were similar for both groups during a median of 3.5 years (range, 1.5 to 7.2 years) of follow-up...
  97. pmc In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile
    Michael J Sorich
    Hematological Malignancies Program and the Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, United States of America
    PLoS Med 5:e83. 2008
    ..Therefore, we measured the in vivo antileukemic effects of MTX and identified genes whose expression differed significantly in patients with a good versus poor response to MTX...
  98. pmc Ancestry and pharmacogenetics of antileukemic drug toxicity
    Shinji Kishi
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 109:4151-7. 2007
    ..026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy...
  99. pmc Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
    Charles G Mullighan
    Department of Pathology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:470-80. 2009
    ..Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined...
  100. doi request reprint Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Cancer 112:1983-91. 2008
    ..The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse...
  101. ncbi request reprint Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance
    C R Yates
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Ann Intern Med 126:608-14. 1997
    ....